Your browser is no longer supported. Please, upgrade your browser.
Settings
ARTL Artelo Biosciences, Inc. daily Stock Chart
ARTL [NASD]
Artelo Biosciences, Inc.
Index- P/E- EPS (ttm)-0.52 Insider Own15.80% Shs Outstand3.28M Perf Week10.89%
Market Cap8.58M Forward P/E- EPS next Y-2.15 Insider Trans0.00% Shs Float2.37M Perf Month30.84%
Income-2.20M PEG- EPS next Q- Inst Own0.60% Short Float0.32% Perf Quarter11.36%
Sales- P/S- EPS this Y-336.10% Inst Trans-52.78% Short Ratio0.22 Perf Half Y137.90%
Book/sh1.82 P/B1.44 EPS next Y-0.90% ROA-104.90% Target Price8.00 Perf Year-
Cash/sh1.34 P/C1.95 EPS next 5Y- ROE-196.20% 52W Range0.80 - 5.00 Perf YTD127.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.66% Beta-
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low227.11% ATR0.31
Employees1 Current Ratio4.30 Sales Q/Q- Oper. Margin- RSI (14)60.33 Volatility13.47% 13.76%
OptionableNo Debt/Eq0.00 EPS Q/Q-105.90% Profit Margin- Rel Volume3.10 Prev Close2.65
ShortableYes LT Debt/Eq0.00 EarningsDec 02 BMO Payout- Avg Volume35.27K Price2.62
Recom2.00 SMA2012.81% SMA5018.48% SMA20027.71% Volume109,398 Change-1.25%
Dec-09-19 08:30AM  Artelo Biosciences Announces Appointment of Seasoned Finance and Industry Executive John W. Beck to Board of Directors GlobeNewswire
Nov-25-19 08:00AM  Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update GlobeNewswire -8.13%
Nov-18-19 08:30AM  Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal GlobeNewswire
Nov-14-19 09:00AM  Artelo Biosciences to Present at the Annual Investival Showcase in London GlobeNewswire
Oct-29-19 08:30AM  Artelo Biosciences Announces Selection of Aptus Clinical Ltd. as Clinical Research Organization for Phase 1b/2a Study of ART27.13 GlobeNewswire -5.65%
Oct-22-19 09:00AM  Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference GlobeNewswire
Sep-18-19 08:00AM  Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine GlobeNewswire
Sep-11-19 09:00AM  Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th ACCESSWIRE +7.29%
Sep-04-19 01:34PM  What Percentage Of Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Do Insiders Own? Simply Wall St.
Jul-15-19 04:01PM  Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-10-19 07:23AM  Cannabis stocks dragged down by CannTrusts losses after cannabis seizure MarketWatch -8.10%
Jun-25-19 01:00PM  Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option GlobeNewswire -6.69%
May-08-19 04:05PM  Artelo Biosciences Retains Crescendo Communications, LLC for Investor Relations Services ACCESSWIRE
Jan-03-19 07:00AM  Artelo Biosciences Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services ACCESSWIRE
Oct-09-18 08:00AM  New Preclinical Cell-Line Data of Artelo Biosciences' ART27.13 Demonstrate Anti-Proliferative Activity in Tumor Models ACCESSWIRE
Jul-03-18 08:00AM  Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium PR Newswire
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system and related signaling pathways. Its product pipeline includes ART27.13, a cannabinoid agonist for the treatment of anorexia associated with cancer; ART12.11, a CBD cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder; and ART26.12, a FABP5 inhibitor for prostate and breast cancer treatment. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is headquartered in La Jolla, California.